Rocket Doctor AI Shares Early Q3 2026 Metrics for U.S. Business Ahead of Global Town Hall

Vancouver-based Rocket Doctor AI Inc. (CSE: AIDR, OTC: AIRDF, Frankfurt: 939) issued a short operational update on Monday covering the first two months of its third fiscal quarter of 2026, ahead of a company-wide global town hall meeting.

The company, which describes itself as a physician-built, AI-enabled healthcare technology platform aimed at helping doctors deliver care and broadening patient access, framed the release as a preview of key performance indicators for its United States operations. The full update is expected to be discussed in greater detail at the town hall.

Progress-to-quarter disclosures of this kind are relatively uncommon among small-cap health technology firms, which typically reserve operational metrics for quarterly filings. By publishing an interim snapshot, Rocket Doctor AI appears to be signaling a cadence of more frequent communication with shareholders as its U.S. footprint develops.

Shares of the broader health-tech and software space were mixed on the day of the announcement. Peer Progress Software (PRGS) traded at $44.05, down 1.35% from its previous close of $44.65, with a market capitalization of roughly $1.81 billion — a reminder that established healthcare-adjacent software names continue to trade at valuations far above emerging pre-revenue-scale platforms like Rocket Doctor AI.

Rocket Doctor AI’s dual listing across the Canadian Securities Exchange, U.S. over-the-counter market, and Frankfurt exchange gives it access to North American and European retail investors, though liquidity on junior exchanges can be thin and share prices volatile relative to large-cap technology peers.

The company has positioned its platform around virtual care delivery, using artificial intelligence tools designed by physicians to support clinical workflows. The sector has attracted attention as health systems seek to extend care capacity amid physician shortages, but early-stage companies in the space face the twin challenges of proving sustainable unit economics and navigating complex regulatory and reimbursement landscapes in the U.S. market.

Monday’s release contained no financial statements, and the company said the update was limited to selected operational measures. Investors and observers will need to wait for fuller disclosures for a complete picture of the quarter.

What to watch

• Details expected from Rocket Doctor AI’s global company town hall following the interim update.
• The company’s full Q3 2026 reporting, which should provide complete financial statements and updated key performance indicators for U.S. operations.
• Any subsequent guidance or milestone announcements regarding expansion of the platform’s U.S. footprint.

Source: original release